Drug Profile
KU 5039
Alternative Names: KU-5039Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Kareus Therapeutics
- Class Antihyperglycaemics; Insulin sensitisers; Small molecules
- Mechanism of Action Adenylate kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Insulin resistance; Type 2 diabetes mellitus
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Insulin-resistance in USA (PO)
- 28 May 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO)
- 18 Apr 2016 Phase-I clinical trials in Insulin resistance in USA (PO)